Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK

Tiarnan D L Keenan, Simon P. Kelly, Ahmed Sallam, Quresh Mohamed, Adnan Tufail, Robert L. Johnston

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Aims: To analyse the incidence and baseline clinical characteristics of patients with neovascular age-related macular degeneration (nAMD) treated with intravitreal anti-vascular endothelial growth factor (VEGF) injections in a defined UK region. Methods: A standardised dataset was collected prospectively using an electronic medical record (EMR) system from 1 January 2008 to 21 June 2012 for all patients living in Gloucestershire who received intravitreal anti-VEGF injections for nAMD. Results: Over the study period, 1207 eyes from 1033 patients began intravitreal anti-VEGF injections for nAMD. The annual incidence in the years after National Institute for Health and Care Excellence (NICE) technology appraisal 155 implementation was stable at 120 (95% CI 110 to 138) eyes or 100 (89 to 115) people per 100 000 population. The most common indication was occult choroidal neovascularisation (51%). Median baseline visual acuity (VA) was significantly higher for second treated than first treated eyes (66 and 56 letters, respectively; p
    Original languageEnglish
    Pages (from-to)1168-1172
    Number of pages4
    JournalBritish Journal Of Ophthalmology
    Volume97
    Issue number9
    DOIs
    Publication statusPublished - Sept 2013

    Fingerprint

    Dive into the research topics of 'Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK'. Together they form a unique fingerprint.

    Cite this